虚增利润占比超95%！贵州百灵违法事实查清，受损股民可索赔

Core Viewpoint - Guizhou BaiLing Pharmaceutical Group Co., Ltd. (Guizhou BaiLing, 002424) is under regulatory scrutiny for suspected violations of information disclosure laws, prompting potential compensation claims from affected investors [1][2]. Summary by Relevant Sections Regulatory Attention - The company has attracted regulatory attention due to alleged information disclosure violations, which may impact investor confidence and stock performance [1]. Compensation Eligibility - Investors who suffered losses are eligible to register for compensation if they meet specific trading conditions: - Time Period One: Investors who bought Guizhou BaiLing stock between April 30, 2020, and April 30, 2024, and sold or continued to hold the stock after April 30, 2024 [1]. - Time Period Two: Investors who bought the stock between April 23, 2022, and April 30, 2024, and sold or continued to hold the stock after April 30, 2024 [1]. Required Documentation for Claims - To participate in the compensation process, investors must prepare the following documents: 1. Original transaction statements for Guizhou BaiLing stock, stamped by the brokerage [2]. 2. Copies of the investor's ID [2]. 3. A securities account inquiry statement issued by the brokerage [2].